# **Bioworld Technology CO., Ltd.**



GCK (R43) Peptide

Cat No.: BS2879P

## Background

Glucokinase (also designated hexokinase IV, HXKIV or GCK) plays a key role in the regulation of glucose-induced insulin secretion. GCK is expressed in pancreatic beta cells where it functions as the major glucose sensor of the body, determining the "set point" for insulin secretion. GCK is also expressed in the liver, where it catalyzes the first committed step in the disposal of glucose. Phosphorylation of glucose by glucokinase appears to be the ratelimiting step for glucose catabolism. A lack of glucokinase activity leads to reduced insulin secretion and hyperglycemia, and has been implicated as a cause for maturity onset diabetes of the youth (MODY). In fact, heterozygous point mutations in the gene encoding GCK have been detected in individuals suffering from MODY.

**Swiss-Prot** 

P35557

**Applications** 

Blocking

### Specificity

This peptide can be used with studies using BS2879 GCK (R43) pAb.

#### **Purification & Purity**

Synthetic peptide GCK (R43). (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### **Product**

1 mg/ml in DI water.

**Storage & Stability** 

Store at  $4 \, \mathbb{C}$  short term. Aliquot and store at  $-20 \, \mathbb{C}$  long term. Avoid freeze-thaw cycles.

#### **Research Use**

For research use only, not for use in diagnostic procedure.